Preparation and the controlled release effect study of graphene oxide-modified poly(ε-caprolactone)

Functionalized graphene oxide-modified poly(ε-caprolactone) composites ((graphene oxide)GO/PCL) were successfully synthesized by Steglich esterification for drug applications of controlled release. Lomefloxacin (LMF) was selected as a model drug to investigate its controlled release properties. The controlled release effect of the LMF-contained pills of the GO/PCL and polylactic acid blend was evaluated. In contrast to the pure PCL, GO/PCL could effectively adjust the time of drug release and release the drug at a constant rate, achieving the controlled release requirements. Furthermore, different additive amounts of graphene oxide have different effects on adjusting the time of controlled release, while the best result obtained under the ratio is 4% GO/PCL as carrier of drug. Thus, high-quality drug carrier materials are obtained which are more suitable for clinical use. Exploring the optimum addition of graphene oxide is very significant for the development of GO/PCL carrier material.